NCT03701061View on ClinicalTrials.gov

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

February 28, 2019

Study Completion Date

January 31, 2020

Conditions
Influenza A Subtype H5N1 Infection
Interventions
BIOLOGICAL

Seasonal Influenza Vaccine

A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study

BIOLOGICAL

Seasonal Influenza Vaccine

A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study

Trial Locations (1)

30030

The Hope Clinic of Emory University, Decatur

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Emory University

OTHER

NCT03701061 - Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response | Biotech Hunter | Biotech Hunter